$BIIB
BIOGEN INC.

2020 Q1 Form 10-Q Financial Statement

#000087504520000011 Filed on April 23, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $3.534B $3.490B
YoY Change 1.28% 11.46%
Cost Of Revenue $454.3M $602.0M
YoY Change -24.53% 34.98%
Gross Profit $3.080B $2.888B
YoY Change 6.66% 7.55%
Gross Profit Margin 87.15% 82.75%
Selling, General & Admin $570.1M $567.7M
YoY Change 0.42% 13.25%
% of Gross Profit 18.51% 19.66%
Research & Development $476.3M $563.7M
YoY Change -15.5% 13.49%
% of Gross Profit 15.46% 19.52%
Depreciation & Amortization $119.9M $121.1M
YoY Change -0.99% -28.3%
% of Gross Profit 3.89% 4.19%
Operating Expenses $1.046B $1.131B
YoY Change -7.51% 13.37%
Operating Profit $1.820B $1.503B
YoY Change 21.11% -2.09%
Interest Expense $44.30M $47.90M
YoY Change -7.52% -5.15%
% of Operating Profit 2.43% 3.19%
Other Income/Expense, Net -$120.5M $357.3M
YoY Change -133.73% -971.46%
Pretax Income $1.699B $1.860B
YoY Change -8.63% 24.52%
Income Tax $292.0M $422.5M
% Of Pretax Income 17.18% 22.72%
Net Earnings $1.399B $1.409B
YoY Change -0.69% 20.11%
Net Earnings / Revenue 39.59% 40.37%
Basic Earnings Per Share $8.10 $7.17
Diluted Earnings Per Share $8.08 $7.15
COMMON SHARES
Basic Shares Outstanding 172.8M shares 196.6M shares
Diluted Shares Outstanding 173.1M shares 197.0M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.860B $3.909B
YoY Change -1.24% -33.92%
Cash & Equivalents $2.591B $2.243B
Short-Term Investments $1.269B $1.666B
Other Short-Term Assets $683.8M $965.4M
YoY Change -29.17% 7.76%
Inventory $858.8M $770.2M
Prepaid Expenses
Receivables $2.093B $2.089B
Other Receivables $0.00 $0.00
Total Short-Term Assets $8.007B $8.943B
YoY Change -10.46% -12.29%
LONG-TERM ASSETS
Property, Plant & Equipment $3.282B $3.014B
YoY Change 8.89% -9.62%
Goodwill $5.752B $5.640B
YoY Change 1.99% 14.91%
Intangibles $3.447B $3.056B
YoY Change 12.78% -19.46%
Long-Term Investments $2.065B $3.236B
YoY Change -36.19% 104.81%
Other Assets $1.131B $1.898B
YoY Change -40.44% 399.42%
Total Long-Term Assets $18.11B $17.50B
YoY Change 3.48% 10.12%
TOTAL ASSETS
Total Short-Term Assets $8.007B $8.943B
Total Long-Term Assets $18.11B $17.50B
Total Assets $26.12B $26.45B
YoY Change -1.23% 1.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $389.0M $378.0M
YoY Change 2.91% 9.31%
Accrued Expenses $1.474B $1.436B
YoY Change 2.65% 18.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.502B
YoY Change
Total Short-Term Liabilities $4.639B $3.149B
YoY Change 47.32% -0.11%
LONG-TERM LIABILITIES
Long-Term Debt $4.460B $5.943B
YoY Change -24.95% 0.24%
Other Long-Term Liabilities $1.357B $1.354B
YoY Change 0.26% -17.45%
Total Long-Term Liabilities $1.357B $1.354B
YoY Change 0.26% -17.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.639B $3.149B
Total Long-Term Liabilities $1.357B $1.354B
Total Liabilities $13.58B $12.62B
YoY Change 7.6% 4.74%
SHAREHOLDERS EQUITY
Retained Earnings $15.67B $17.03B
YoY Change -7.95% -1.78%
Common Stock $100.0K $100.0K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.977B $2.977B
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $12.55B $13.83B
YoY Change
Total Liabilities & Shareholders Equity $26.12B $26.45B
YoY Change -1.23% 1.36%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income $1.399B $1.409B
YoY Change -0.69% 20.11%
Depreciation, Depletion And Amortization $119.9M $121.1M
YoY Change -0.99% -28.3%
Cash From Operating Activities $1.467B $1.460B
YoY Change 0.53% 0.16%
INVESTING ACTIVITIES
Capital Expenditures $149.7M $127.1M
YoY Change 17.78% -34.72%
Acquisitions
YoY Change
Other Investing Activities $500.0K -$1.700M
YoY Change -129.41% 6.25%
Cash From Investing Activities $442.9M $238.8M
YoY Change 85.47% -82.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.220B $655.8M
YoY Change 238.55% 162.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$2.245B -$679.3M
YoY Change 230.53% 152.9%
NET CHANGE
Cash From Operating Activities $1.467B $1.460B
Cash From Investing Activities $442.9M $238.8M
Cash From Financing Activities -$2.245B -$679.3M
Net Change In Cash -$335.1M $1.019B
YoY Change -132.89% -59.8%
FREE CASH FLOW
Cash From Operating Activities $1.467B $1.460B
Capital Expenditures $149.7M $127.1M
Free Cash Flow $1.318B $1.332B
YoY Change -1.11% 5.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 biib Average Maturity Of Marketable Securities
AverageMaturityOfMarketableSecurities
P14M
CY2020Q1 biib Average Maturity Of Marketable Securities
AverageMaturityOfMarketableSecurities
P14M
CY2019Q4 biib Investment In Biotechnology Companies That Are Determined To Be Unconsolidated Variable Interest Entities
InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
22700000 USD
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000875045
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0005
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0005
CY2019Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2020Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
0-19311
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
BIOGEN INC.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0112644
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
225 Binney Street
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2020Q1 dei City Area Code
CityAreaCode
617
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
679-2000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68200000 USD
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0005 par value
CY2020Q1 dei Trading Symbol
TradingSymbol
BIIB
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
163187486 shares
CY2020Q1 us-gaap Revenues
Revenues
3534300000 USD
CY2019Q1 us-gaap Revenues
Revenues
3489800000 USD
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2019Q1 us-gaap Translation Adjustment For Net Investment Hedge Net Of Tax Period Increase Decrease
TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
14000000.0 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-800000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
454300000 USD
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
602000000.0 USD
CY2020Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
476300000 USD
CY2019Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
563700000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
570100000 USD
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
567700000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
71500000 USD
CY2020Q1 biib Collaborationprofitlosssharing
Collaborationprofitlosssharing
71800000 USD
CY2019Q1 biib Collaborationprofitlosssharing
Collaborationprofitlosssharing
58100000 USD
CY2020Q1 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
0 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
4600000 USD
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-11500000 USD
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2019Q1 us-gaap Restructuring Charges
RestructuringCharges
400000 USD
CY2020Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
75000000.0 USD
CY2019Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
1714400000 USD
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
1987100000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1819900000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1502700000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120500000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
357300000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1699400000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1860000000.0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
292000000.0 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
422500000 USD
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-14800000 USD
CY2019Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-28700000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
1392600000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
1408800000 USD
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-6500000 USD
CY2019Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1399100000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
1408800000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.10
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.17
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.08
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.15
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172800000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
196600000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
173100000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197000000.0 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1399100000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
1408800000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7800000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5900000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1379100000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6900000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
33800000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
16900000 USD
CY2020Q1 us-gaap Translation Adjustment For Net Investment Hedge Net Of Tax Period Increase Decrease
TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
23000000.0 USD
CY2019Q4 us-gaap Assets
Assets
27234300000 USD
CY2020Q1 us-gaap Notes Payable Current
NotesPayableCurrent
1501800000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1495800000 USD
CY2020Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
310000000.0 USD
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
71400000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-600000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-63900000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17800000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14100000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
20600000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1385000000.0 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1429400000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1429400000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2591300000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2913700000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1269100000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1562200000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2092600000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1880500000 USD
CY2020Q1 biib Duefromanti Cd20therapeuticprograms
DuefromantiCD20therapeuticprograms
511600000 USD
CY2019Q4 biib Duefromanti Cd20therapeuticprograms
DuefromantiCD20therapeuticprograms
590200000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
858800000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
804200000 USD
CY2020Q1 us-gaap Other Assets Current
OtherAssetsCurrent
683800000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
631000000.0 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
8007200000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
8381800000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
969500000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1408100000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3281600000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3247300000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
422000000.0 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
427000000.0 USD
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3446900000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3527400000 USD
CY2020Q1 us-gaap Goodwill
Goodwill
5752000000.0 USD
CY2019Q4 us-gaap Goodwill
Goodwill
5757800000 USD
CY2020Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3109400000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3232100000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1130600000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1252800000 USD
CY2020Q1 us-gaap Assets
Assets
26119200000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
389000000.0 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
530800000 USD
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2437800000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2765800000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4638600000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4863800000 USD
CY2020Q1 us-gaap Long Term Debt
LongTermDebt
4459900000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
4459000000.0 USD
CY2020Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2722800000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2810800000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
403700000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
412700000 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1357300000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1348900000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
13582300000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
13895200000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
100000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-149300000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-135200000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15673100000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
16455400000 USD
CY2020Q1 us-gaap Treasury Stock Value
TreasuryStockValue
2977100000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2977100000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
12546900000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13343200000 USD
CY2020Q1 us-gaap Minority Interest
MinorityInterest
-10000000.0 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
-4100000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12536900000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13339100000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26119200000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27234300000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
1392600000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
1408800000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
119900000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
121100000 USD
CY2020Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
75000000.0 USD
CY2019Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
67700000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
45700000 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
4600000 USD
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-11500000 USD
CY2020Q1 us-gaap Income Loss From Individually Significant Component Disposed Of Or Held For Sale Excluding Discontinued Operations Attributable To Parent Before Income Tax
IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
0 USD
CY2019Q1 us-gaap Income Loss From Individually Significant Component Disposed Of Or Held For Sale Excluding Discontinued Operations Attributable To Parent Before Income Tax
IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
-115500000 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
36900000 USD
CY2019Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
228000000.0 USD
CY2019Q1 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
0 USD
CY2020Q1 us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-62000000.0 USD
CY2019Q1 us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
375000000.0 USD
CY2020Q1 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
0 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-45700000 USD
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-50700000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
238400000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
136600000 USD
CY2020Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-78600000 USD
CY2019Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
0 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
62200000 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-129000000.0 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-347400000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-138400000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
223000000.0 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
170300000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-18500000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
171100000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1467300000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1459500000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
2389300000 USD
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1489200000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1684700000 USD
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
825000000.0 USD
CY2020Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0 USD
CY2019Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
300000000.0 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
149700000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
127100000 USD
CY2020Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
75000000.0 USD
CY2019Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 USD
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
37000000.0 USD
CY2019Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2020Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
500000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
0 USD
CY2020Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
500000 USD
CY2019Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-1700000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
442900000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
238800000 USD
CY2020Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2220200000 USD
CY2019Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
655800000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
29600000 USD
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
32200000 USD
CY2020Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
4500000 USD
CY2019Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
8700000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1224600000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-400000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2913700000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2591300000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2243200000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
12700000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2245300000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-679300000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-335100000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1019000000.0 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13343200000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13339100000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1399100000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
1392600000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14100000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13500000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
18100000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
18100000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-47800000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-47800000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-69200000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-69200000 USD
CY2020Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
600000 USD
CY2020Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
600000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
12546900000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12536900000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13031600000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
1408800000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
20600000 USD
CY2019Q1 biib Noncontrollinginterestincreasedecreaseother
Noncontrollinginterestincreasedecreaseother
100000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
16600000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48900000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49000000.0 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13822000000.0 USD
CY2020Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2020Q1 biib Interest In Subsidiary
InterestInSubsidiary
1
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2019Q2 biib Clinical Assets Acquired
ClinicalAssetsAcquired
2 Assets
CY2020Q1 us-gaap Tax Basis Of Investments Cost For Income Tax Purposes
TaxBasisOfInvestmentsCostForIncomeTaxPurposes
0 USD
CY2019Q3 biib Inventoryrawmaterialssoldto Fujifilm
InventoryrawmaterialssoldtoFUJIFILM
41800000 USD
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1198900000 USD
CY2020Q1 biib Current Provisions To Product Revenue Reserves Relating To Sales In Current Year
CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
1033300000 USD
CY2020Q1 biib Adjustments To Product Revenue Reserves Relating To Sales In Prior Years
AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
16900000 USD
CY2020Q1 biib Payments Returns Applied Against Product Revenue Reserves Relating To Current Year
PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
383700000 USD
CY2020Q1 biib Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year
PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
549800000 USD
CY2020Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1281800000 USD
CY2020Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1281800000 USD
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1198900000 USD
CY2020Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
210900000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
169700000 USD
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
475200000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
460000000.0 USD
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
172700000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
174500000 USD
CY2020Q1 biib Inventorynetcurrentandnoncurrent
Inventorynetcurrentandnoncurrent
858800000 USD
CY2019Q4 biib Inventorynetcurrentandnoncurrent
Inventorynetcurrentandnoncurrent
804200000 USD
CY2020Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8399800000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4952900000 USD
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3446900000 USD
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8408800000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4881400000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3527400000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
71500000 USD
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68200000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
193000000.0 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
220000000.0 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
220000000.0 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
230000000.0 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
230000000.0 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
220000000.0 USD
CY2019Q4 us-gaap Goodwill
Goodwill
5757800000 USD
CY2020Q1 us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
-5800000 USD
CY2020Q1 us-gaap Goodwill
Goodwill
5752000000.0 USD
CY2020Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 USD
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2020Q1 us-gaap Servicing Asset At Fair Value Changes In Fair Value Resulting From Changes In Valuation Inputs Or Changes In Assumptions
ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions
0 USD
CY2020Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
6681300000 USD
CY2020Q1 us-gaap Notes Payable
NotesPayable
5961700000 USD
CY2019Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
6553600000 USD
CY2019Q4 us-gaap Notes Payable
NotesPayable
5954800000 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
4600000 USD
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-11500000 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0 USD
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
194200000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
197700000 USD
CY2020Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1974100000 USD
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2541100000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2247000000.0 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7700000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16100000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2238600000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2965000000.0 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000000.0 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
700000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2970300000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1269100000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1267700000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1562200000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1560800000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
846000000.0 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
856300000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
1234500000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1230400000 USD
CY2020Q1 biib Available For Sale Securities Debt Maturities After Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
123500000 USD
CY2020Q1 biib Available For Sale Securities Debt Maturities After Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
123000000.0 USD
CY2019Q4 biib Available For Sale Securities Debt Maturities After Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
173600000 USD
CY2019Q4 biib Available For Sale Securities Debt Maturities After Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
173800000 USD
CY2020Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2238600000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2247000000.0 USD
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2970300000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2965000000.0 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
2389300000 USD
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1489200000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
5700000 USD
CY2019Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
600000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
19100000 USD
CY2019Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
300000 USD
CY2020Q1 biib Unrealized Gain Losses On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
-34400000 USD
CY2019Q4 biib Unrealized Gain Losses On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
500000 USD
CY2020Q1 biib Unrealized Gain Losses On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
-34400000 USD
CY2020Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
2400000 USD
CY2019Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-4800000 USD
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1636700000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1590900000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
48400000 USD
CY2019Q1 us-gaap Depreciation
Depreciation
52900000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-135200000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
700000 USD
CY2020Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-14800000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14100000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-149300000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-240400000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
37300000 USD
CY2019Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-16700000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
20600000 USD
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219800000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1399100000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
1408800000 USD
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172800000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
196600000 shares
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
300000 shares
CY2019Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
400000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
173100000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197000000.0 shares
CY2020Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
76400000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
49500000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1500000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3300000 USD
CY2020Q1 biib Share Based Compensation Expense Included In Costs And Expenses
ShareBasedCompensationExpenseIncludedInCostsAndExpenses
74900000 USD
CY2019Q1 biib Share Based Compensation Expense Included In Costs And Expenses
ShareBasedCompensationExpenseIncludedInCostsAndExpenses
46200000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
13300000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
7400000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
76400000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
49500000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1500000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3300000 USD
CY2020Q1 biib Share Based Compensation Expense Included In Costs And Expenses
ShareBasedCompensationExpenseIncludedInCostsAndExpenses
74900000 USD
CY2019Q1 biib Share Based Compensation Expense Included In Costs And Expenses
ShareBasedCompensationExpenseIncludedInCostsAndExpenses
46200000 USD
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.006
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.004
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.041
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.046
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.010
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.008
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Depreciation And Amortization
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
0.002
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Depreciation And Amortization
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
0.003
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Assets
EffectiveIncomeTaxRateReconciliationDispositionOfAssets
0
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Assets
EffectiveIncomeTaxRateReconciliationDispositionOfAssets
0.043
CY2020Q1 biib Effective Tax Rate Reconciliation Gilt Itax
EffectiveTaxRateReconciliationGILTItax
0.006
CY2019Q1 biib Effective Tax Rate Reconciliation Gilt Itax
EffectiveTaxRateReconciliationGILTItax
0.019
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.002
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.004
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2019Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.172
CY2019Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.227
CY2019Q4 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
75000000.0 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
24400000 USD
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
31200000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
44300000 USD
CY2019Q1 us-gaap Interest Expense
InterestExpense
47900000 USD
CY2020Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-77300000 USD
CY2019Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
376400000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-18900000 USD
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2200000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4400000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-200000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120500000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
357300000 USD
CY2020Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-77300000 USD
CY2019Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
376400000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-60900000 USD
CY2019Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
375300000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
0 USD
CY2019Q1 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
800000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-60900000 USD
CY2019Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
376100000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
190300000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
309100000 USD
CY2020Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
209900000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
220900000 USD
CY2020Q1 biib Collaborationexpensesaccrual
Collaborationexpensesaccrual
154600000 USD
CY2019Q4 biib Collaborationexpensesaccrual
Collaborationexpensesaccrual
281600000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
147300000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
148400000 USD
CY2020Q1 us-gaap Construction Payable Current And Noncurrent
ConstructionPayableCurrentAndNoncurrent
27300000 USD
CY2019Q4 us-gaap Construction Payable Current And Noncurrent
ConstructionPayableCurrentAndNoncurrent
78000000.0 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
662000000.0 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
726700000 USD
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2437800000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2765800000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1357300000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1348900000 USD
CY2020Q1 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
801300000 USD
CY2019Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
803300000 USD
CY2020Q1 biib Investment In Biotechnology Companies That Are Determined To Be Unconsolidated Variable Interest Entities
InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
22700000 USD
CY2019Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
200000000.0 USD

Files In Submission

Name View Source Status
0000875045-20-000011-index-headers.html Edgar Link pending
0000875045-20-000011-index.html Edgar Link pending
0000875045-20-000011.txt Edgar Link pending
0000875045-20-000011-xbrl.zip Edgar Link pending
biib-20200331.xsd Edgar Link pending
biib-20200331_cal.xml Edgar Link unprocessable
biib-20200331_def.xml Edgar Link unprocessable
biib-20200331_lab.xml Edgar Link unprocessable
biib-20200331_pre.xml Edgar Link unprocessable
biib-2020331x10q.htm Edgar Link pending
biib-2020331x10q_htm.xml Edgar Link completed
biib-2020331xex311.htm Edgar Link pending
biib-2020331xex312.htm Edgar Link pending
biib-2020331xex321.htm Edgar Link pending
biogenlogoa10.jpg Edgar Link pending
chart-0b79355e2c74500eae0.jpg Edgar Link pending
chart-0e90e35cb3f356fdb65.jpg Edgar Link pending
chart-12ab3b9cf42c502a82c.jpg Edgar Link pending
chart-21a631c632245214b5c.jpg Edgar Link pending
chart-23a7c01770e356d29ff.jpg Edgar Link pending
chart-2dae770040575c09957.jpg Edgar Link pending
chart-4bc2b65e63bf598aaeb.jpg Edgar Link pending
chart-5576b2a7fe2b5bfabd8.jpg Edgar Link pending
chart-7f0043a713055b78858.jpg Edgar Link pending
chart-80323542940f5f3e9fd.jpg Edgar Link pending
chart-8808588ca10451cd818.jpg Edgar Link pending
chart-9c451125cbd651c0abd.jpg Edgar Link pending
chart-9f17d12ff13d514ba12.jpg Edgar Link pending
chart-a0675ec327835197bd6.jpg Edgar Link pending
chart-a8b4db707bd75762992.jpg Edgar Link pending
chart-bec93acf6eb55fb08e4.jpg Edgar Link pending
chart-d3a8fa49540b5980939.jpg Edgar Link pending
chart-d48ca46993295751b22.jpg Edgar Link pending
chart-db872ef72f75548e83c.jpg Edgar Link pending
chart-dffb73ef4c6252a6985.jpg Edgar Link pending
chart-e41c9713c67058c3bab.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending